This newsletter presents you the following key sessions:
1. Adding amivantamab to chemotherapy improves efficacy outcomes in patients with non-small cell lung
cancer harbouring EGFR exon 20 insertion mutations
2. Belzutifan significantly outperforms everolimus in previously treated patients with advanced clear cell
renal carcinoma
3. Improved clinical outcomes with [177Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic
castration-resistant prostate cancer
4. Datopotamab deruxtecan improves efficacy outcomes and safety in patients with advanced or metastatic
non-squamous non-small cell lung cancer
5. Dostarlimab plus chemotherapy provides clinical benefit to patients with primary advanced or recurrent
endometrial carcinoma, irrespective of the molecular subtype